Insight

Jun 30, 2024, 14:51

Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer

Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper by Myriam Chalabi et al. titled “Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer” published in The New England Journal of Medicine:

Sergio Cifuentes commented on X sharing this paper:

“Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer: 98% timely surgery, 95% major pathological response, 0 recurrences in 26 months.”

Source: Sergio Cifuentes/X

Anja Van Lent Brechtje Grotenhuis cancer Cecile Grootscholten CENEIT México dMMR dMMR colon cancer Eduard Hendriks Emile Voest Geerard Beets Inge Huibregtse ipilimumab Jacobus Burger John Haanen José van den Berg June Rogers Colon Cancer Research Fund. Koert Kuhlmann Lodewyk Wessels Monique Van Leerdam Myriam Chalabi Neoadjuvant nivolumab plus ipilimumab Nikè Büller nivolumab OncoDaily Oncology Pedro Batista Tan Petur Snaebjornsson Regina Beets-Tan Sara Balduzzi Sergio Cifuentes Simone Dokter Steven Oosterling Tjeerd Aukema Ton Schumacher Yara Verschoor

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage